Redwood Pharma

4 articles about Redwood Pharma

• Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

  5/31/2023

  Redwood Pharma AB (publ) announces positive results from the company's clinical study with RP501, a medical technology self-care product being developed for the treatment of dry eye.

• Accelerating development of RP501 first-line therapy for dry eye disease

  10/25/2021

  Redwood Pharma announces a strategic move to accelerate development of RP501, the company's IntelliGel-based topical first-line therapy for dry eye disease.

• BIO2016: Redwood Pharma To Present At BIO 2016 In San Francisco

  6/7/2016

• Redwood Pharma Raises SEK 6.6 Million In Private Placement

  2/23/2016